- 1、本文档共62页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 美国国会的态度 1988 report from the U.S. Congress Office of Technology Assessment Mapping Our Genes-Genome Projects: How Big? How Fast? NTIS order #PB88-212402 人类基因组计划的实施—负责人 第一任首席科学家: James Watson 因DNA顺序专利争论 于1992年辞职. 第二任首席科学家 Francis Collins Watson与Venter关于DNA顺序专利之争(1) That newfound harmony was shattered in June 1991, when Venter, who ran a large sequencing lab at the National Institute for Neurological Disorders and Stroke, went public with an iconoclastic plan: Why not focus on finding the genes--the real goods that both scientists and companies were clamoring for--and leave tedious sequencing until later? Venter and colleague Mark Adams had developed a new technique, called expressed sequence tags, that enabled them to find genes at unprecedented speed. Never one of Watsons inner circle, Venter boasted that this new approach was a bargain in comparison to the genome project and claimed he could find 80% to 90% of the genes within a few years, for a fraction of the cost (Science, 21 June 1991, p. 1618). Watson dismissed Venters cream-skimming approach, but their feud remained subterranean until a few weeks later, when Venter described his work at a congressional hearing. NIH was so impressed with his progress, Venter said, that it was filing patent applications on the partial genes he was identifying--at a rate of 1000 a month. Watson与Venter关于DNA顺序专利之争(2) Watson erupted, denouncing the patenting scheme as sheer lunacy and noting that virtually any monkey could do what Venters group was doing (Science, 11 October 1991, p. 184). What irked him was that Venter and NIH had no clue about the function of the genes from which these fragments came. If the patents held, that meant anybody could lay claim to most of the human genes, undercutting patent protection for b
文档评论(0)